Ultrahigh-throughput discovery of modified aptamers as specific and potent enzyme inhibitors

ABSTRACT: Enzymes are instrumental to life and key actors of pathologies, making them relevant drug targets. Most enzyme inhibitors consist of small molecules. Although efficient, their development is long, costly and can come with unwanted off-targeting. Substantial gain in specificity and discovery efficiency is possible using biologicals. Best exemplified by antibodies, these drugs derived from living systems display high specificity and their development is eased by harnessing natural evolution. Aptamers are nucleic acids sharing functional similarities with antibodies while being deprived of many of their limitations. Yet, the success rate of inhibitory aptamer discovery remained hampered by the lack of an efficient discovery pipeline. In this work, we addressed this issue by introducing an ult

INSTRUMENT(S): Illumina MiSeq

ORGANISM(S): synthetic construct

SUBMITTER: Roger Cubi Piqué 

PROVIDER: E-MTAB-14407 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress